Cria Technologies

compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and marketing medical devices, the provision of regulatory frameworks and the support with regulatory expert human ressources. compliag is manufacturer and distributor of the vr therapy solution moovly.

MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new therapies and harnessing the potential of Sonelokimab, a novel investigational Nanobody®, to transform results for patients experiencing inflammation.

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.

Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to end the threat of antimicrobial resistance through an AI-powered technology.

At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommon diseases with significant unmet medical needs.

AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They have three products currently undergoing clinical trials, with a specific focus on neurodegenerative diseases. The company's primary goal is to create and develop therapeutic and diagnostic products that can both prevent and modify diseases caused by misfolding proteins. AC Immune utilizes two distinct technology platforms to create antibodies, small molecules, and vaccines for a wide range of neurodegenerative indications.

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. AlveoliX aims at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe bacterial infections and combat antibiotics resistance.

MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat and rehab patients. It develops medical grade virtual reality products to stimulate neural recovery. It also develops a platform to build intuitive human machine interfaces combining VR, computer graphics, brain imaging, and neuroscience. MindMaze offers MindMotionPRO, which provides patients with engaging and motivational virtual reality rehabilitation programs that support their recovery goals enabling them to follow a personalized exercise regimen prescribed by the rehabilitation expert. It promotes the ability of clinicians to design and personalize the dose and modality of a range of therapies and provides hospitals with the ability to optimize the delivery of rehabilitation therapy. MindMaze’s technology includes user interfaces, including a lightweight wearable head mounted display and 3D motion capture cameras that offer VR, gesture, and multiple object/user recognition and augmented reality capabilities, and medical grade technology enables new applications in gaming, brain machine control, and healthcare. It also offers motion capture technology and analysis, immersive virtual reality, and neurophysiological measurements and analysis solutions. Tej Tadi founded MindMaze on May 24, 2012. Its headquarters is in Lausanne in Switzerland with additional locations in Zürich and Ecublens in the same country and San Francisco in California in the United States.

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinical devices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients.

Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to patients as an alternative to injected therapies for hereditary angioedema and other related conditions. Their lead drug candidate, PHA121, is a potent small-molecule bradykinin B2 receptor antagonist currently in Phase 1 clinical study. The co-founders of Pharvaris include the inventor of icatibant and key leaders from Jerini AG, who developed icatibant for HAE treatment, now marketed as Firazyr® by Takeda.

Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.